Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
Shannon Puhalla, Adam BrufskyUPMC Magee-Womens Cancer Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a new...
Main Authors: | Shannon Puhalla, Adam Brufsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-09-01
|
Series: | Biologics : Targets & Therapy |
Online Access: | http://www.dovepress.com/ixabepilone-a-new-chemotherapeutic-option-for-refractory-metastatic-br-a2300 |
Similar Items
-
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
by: Marta Vallee Cobham, et al.
Published: (2009-06-01) -
Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
by: Nuhad K. Ibrahim
Published: (2021-07-01) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
by: Massimo Cristofanilli
Published: (2012-01-01) -
Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01) -
Ixabepilone: new perspectives for its use in breast cancer
by: A. A. Mescheryakov, et al.
Published: (2018-11-01)